Example: Heart Attack

Clinical Trials Sponsored by Protalix

Total 17 results

NCT04552691

Available

Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

Conditions: Fabry Disease
NCT03614234

Enrolling by invitation

Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients

Conditions: Fabry Disease
NCT03566017

Enrolling by invitation

Extension Study of 1 mg/kg Pegunigalsidase Alfa in Patients With Fabry Disease

Conditions: Fabry Disease
NCT03180840

Active, not recruiting

Study of the Safety, Efficacy, & PK of Pegunigalsidase Alfa (PRX-102) 2 mg/kg IV Administered Every 4 Weeks in Fabry Disease Patients

Conditions: Fabry Disease
NCT03018730

Completed

Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)

Conditions: Fabry Disease
NCT02921620

Withdrawn

Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease

Conditions: Fabry Disease
NCT02795676

Active, not recruiting

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

Conditions: Fabry Disease
NCT02768974

Unknown status

Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis

Conditions: Ulcerative Colitis
NCT02722122

Unknown status

Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®

Conditions: Cystic Fibrosis
NCT02605590

Completed

Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers

Conditions: Cystic Fibrosis (CF)
NCT02107846

Completed

An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112

Conditions: Gaucher Disease
NCT02107833

Completed

Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers

Conditions: Human Volunteer
NCT01981720

Active, not recruiting

Extension Study of PRX-102 for up to 60 Months

Conditions: Fabry Disease
NCT01747980

Completed

Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients

Conditions: Gaucher Disease
NCT01678898

Completed

Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients

Conditions: Fabry Disease
NCT01093859

Completed

An Exploratory Phase 1 Microdose Study of PRX-105

Conditions: Organophosphate Exposure
NCT00258778

Completed

Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)

Conditions: Gaucher Disease